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Abstract
Recently, two large randomized controlled trials of distinct biologic therapies in systemic lupus
erythematosus, B-cell depletion with rituximab and co-stimulatory blockade with CTLA4Ig
(abatacept), failed to meet primary endpoints. Given the great need for new treatments in lupus,
these results were met with disappointment and have left the rheumatology and immunology
community searching for an explanation. Are these experimental agents ineffective in lupus or are
there trial design issues or other considerations? In this commentary, we discuss our perspective on
these results within the context of current understanding of the pathophysiology of lupus and the
mechanism of action of biologic therapies.
Introduction and context
Systemic lupus erythematosus (SLE) is a complex
autoimmune disease with considerable heterogeneity,
characterized by dysregulation of the immune system
and production of hallmark autoantibodies. Because this
disease continues to be associated with significant
morbidity and a three- to fivefold increased mortality
compared to the general population, there is great
interest in the development of new and targeted
treatment approaches [1]. Current treatments are gen-
erally broadly immunosuppressive and thus fraught with
complications and sometimes lack of efficacy. However,
major obstacles in finding efficacious therapies for SLE
include the challenges of clinical trial design given the
low prevalence of disease, great clinical heterogeneity,
relapsing-remitting course, and lack of well-established
endpoints [2–5]. These challenges have contributed to
the fact that there have been no new drugs approved for
the treatment of SLE in over 50 years.
Despite these difficulties, there is reason for optimism.
A great deal of effort toward improving lupus clinical
trial methodology has come from OMERACT (Outcome
Measures in Rheumatology) [6], the US Food and Drug
Administration (FDA) clinical trial guidelines [7], the
Systemic Lupus International Collaborating Clinics
conference, and EULAR (European League Against
Rheumatism) [5]. Moreover, our understanding about
the pathogenesis of SLE has grown substantially in the
past decade, leading to an explosion of promising
biologic therapies.
Although multiple immunologic abnormalities are
undoubtedly important for the development and clinical
expression of SLE, a large body of evidence strongly
points to the B cell as a central player in the pathogenesis
of this disease [8]. The disease is characterized not only
by defects in B-cell development, homeostasis, signaling,
and tolerance but also by abnormalities in cytokines and
chemokines either produced by B cells or with important
B-cell influences [8]. B cells may participate in the
immune dysregulation of SLE at multiple levels; serving
as the precursors of antibody-secreting cells, taking up
and presenting autoantigens to T cells, helping to
regulate and organize inflammatory responses through
cytokine and chemokine secretion (such as interleukin-
10, interleukin-6, interferon-g, and lymphotoxin-a), and
regulating other immune cells. The importance of these
latter functions has been clearly demonstrated in murine
SLE, where B cells have been found to be critical to the
development of disease even when they are unable to
secrete autoantibodies [9].
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alities in the B-cell compartment in SLE, a rational
approach to treatment involves B-cell depletion. FDA-
approved for lymphoma and rheumatoid arthritis
refractory to anti-tumor necrosis factor (TNF), B-cell
depletion with the anti-CD20 monoclonal antibody
rituximab has also shown benefit in open-label studies
and case series (often for severe, refractory cases) for
many other autoimmune diseases. As for SLE, our initial
phase I/II study [10] and other similar open-label trials
have provided strong support for this therapy, which has
become a useful tool for refractory SLE with either renal,
central nervous system, or hematological involvement
[11–16]. Given the growing familiarity amongst rheu-
matologists with using this therapy in rheumatoid
arthritis, there is expanding off-label use in other
rheumatic diseases including SLE.
Rituximab is by no means the only promising biologic
therapy under investigation in SLE. As an alternative to
selective B-cell depletion, there has been great interest in
targeting co-stimulatory signaling pathways as well as
antagonizing cytokines that have prominent B-cell
effects. Belimumab is a fully human monoclonal anti-
body that neutralizes soluble B-cell activating factor of
the TNF family (BAFF), a cytokine important for B-cell
survival and plasma cell differentiation. Mice over-
expressing BAFF develop an SLE-like phenotype [17].
Moreover, lupus-prone mice have elevated levels of
circulating BAFF, and administration of soluble BAFF
receptors ameliorates disease progression and improves
survival [18].
Blockade of co-stimulatory interactions between B7 on
antigen-presenting cells (including B cells) and CD28
on T cells can also prevent activation of B cells in SLE.
A fusion protein of the extracellular domain of cytotoxic
T-lymphocyte antigen (CTLA) and immunoglobulin
constant regions, CTLA4Ig, binds to B7 at a much higher
affinity than CD28, thus blocking CD28-mediated
co-stimulation and activation of T cells. CTLA4Ig
(abatacept) is FDA approved for the treatment for
rheumatoid arthritis [19] and, thus, similar to rituximab,
is theoretically available for off-label use in SLE. In
murine SLE, CTLA4Ig has demonstrated remarkable
efficacy, improving both renal disease and survival [20].
Recent advances
Randomized controlled trials evaluating either rituximab
or abatacept in the treatment of SLE have not been
available until the recently reported studies at the 2008
American College of Rheumatology meeting. Merrill
et al. [21,22] reported the EXPLORER trial, a
randomized, double-blind, placebo-controlled trial
comparing rituximab to placebo in a 2:1 randomization
in 257 active non-renal lupus patients. Inclusion criteria
required at least one organ with British Isles Lupus
Assessment Group (BILAG) A (severe disease activity) or
at least two organs with BILAG B (moderate disease
activity) at study entry while taking immune suppressive
treatment. Two doses of 1,000 mg rituximab given 2
weeks apart were administered at baseline and again at 6
months. All patients continued their baseline treatments
and received a 10 week course of high dose steroids up to
0.5 to 1.0 mg/kg depending on baseline steroids and the
severity of their disease, with taper over an additional 8
weeks. The proportion of subjects achieving a partial
clinical response (PCR) or major clinical response
(MCR) at 52 weeks, with a primary endpoint as defined
in Table 1, was no different in the treatment group
(24.9% PCR including MCR) versus the placebo group
(27.3%). There were also no differences between the
groups for any of the pre-defined, mostly BILAG-based,
secondary endpoints. Both groups had significant and
sustained decreases in global BILAG and Systemic Lupus
Erythematosus Disease Activity Index (SLEDAI) scores
over time. In a pre-specified subgroup analysis of black
and Hispanic subjects, who overall had lower placebo
responses (15.7% PCR including MCR), there was a
statistically significant difference with the addition of
rituximab (33.8% PCR including MCR). Additionally,
the subgroup of patients receiving methotrexate began to
diverge at the end of the study, with a statistically
significant increase in the placebo group disease activity
and sustained response in the rituximab treated group.
Finally, there was a suggestion of serological efficacy
given the improvement in anti-DNA titers and comple-
ment levels in both groups, but with significant
separation over time favoring rituximab. Overall, we
conclude that the EXPLORER trial did not demonstrate
clinical efficacy of rituximab in SLE since it did not meet
any of the primary or secondary endpoints. However, the
outcome suggests that most SLE patients with non-renal
disease respond well to high dose steroids, and other
immunosuppressive agents appear to be effective in
maintaining a response, making it difficult to demon-
strate a benefit of drug with this study design.
Merrill et al. also reported on an efficacy study of
abatacept (CTLA4Ig) in reducing flares in non-renal SLE
patients with active polyarthritis, serositis, or discoid
lesions. This double-blind, placebo-controlled phase II
trial randomized 180 subjects 2:1 to abatacept (10 mg/kg
every other week for three doses, then monthly) or
placebo for 1 year. Prednisone at 30 mg per day was
given for 1 month and then tapered per protocol. The
primary endpoint was the proportion of patients with a
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taper over 1 year. There was no difference in the flare
rates between the treatment group (79.7%) and placebo
group (82.5%) or any of the secondary BILAG endpoints.
In post hoc analyses, the question of whether BILAG B
flare might be too stringent an endpoint to distinguish
between placebo and active treatment was examined. An
increased trend towards efficacy was found in the
polyarthritis subgroup (95 patients) when only BILAG
A flares were counted (36.5% in abatacept-treated
patients versus 62.5% in the placebo group). When
physician assessment was used to determine flare there
was a difference in overall flare endpoint (63.6% in the
abatacept group versus 82.3% in the placebo group). In
addition, the proportion of patients who were on less
than 7.5 mg prednisone and also rated to have no flare
during months 10–12 was significantly higher in the
abatacept group (42.4 versus 28.1% in the placebo
group). As with the prior trial, we conclude that this
study did not demonstrate efficacy of abatacept in non-
renal SLE since the primary and secondary endpoints
were not met. However, the post hoc analyses suggest to us
that the outcome measures used were suboptimal and
also that there may be greater efficacy of abatacept in the
polyarthritis subset of disease.
As a point of comparison, belimumab (fully human
monoclonal antibody against BAFF) for SLE has also
been evaluated in a double-blind, placebo-controlled
trial. Long-term follow-up for this trial was also
presented at the American College of Rheumatology
2008 meeting [23]. This study did not meet its original
primary efficacy endpoint, which was the change in the
Safety of Estrogen in Lupus Erythematosus National
Assessment (SELENA)-SLEDAI score at week 52. How-
ever, 28% of patients were not serologically active
[serologically active patients were defined as antinuclear
antibody positive (+ANA) or anti-double-stranded DNA
(dsDNA) positive and represented 72% (n = 321) of
study patients]. When only the serologically active
subjects were analyzed post hoc, there was a statistically
significant improvement in disease activity using a novel
responder index [the SLE responder index (SRI)] based
on a SELENA-SLEDAI improvement of four or more, no
new BILAG 1A or 2B flares, and no worsening on the
Physicians Global Assessment. As defined by the SRI,
belimumab-treated seropositive subjects achieved a 46%
response at week 52 versus 29% of placebo-treated
subjects (P < 0.05). With open-label therapy, the SRI
response increased to 55% by week 76 and persisted
through 160 weeks. By week 52, 62% of belimumab-
treated seropositive subjects had SELENA-SLEDAI flares
versus 74% of placebo-treated subjects (P-values not
significant). During long-term open treatment, the
frequency of SELENA-SLEDAI flares declined to 7% at
3 years, suggestive of sustained improvement of disease
activity with long-term therapy. Overall, we conclude
that belimumab may have efficacy in non-renal SLE,
particularly over long-term treatment, results that need
to be confirmed in ongoing randomized studies with
appropriately selected SLE patients and refined primary
endpoints.
Implications for clinical practice
There are two broad explanations for the negative results
of these two recently reported major trials: either the
drugs are not effective or the trial design was suboptimal
for demonstrating clinical efficacy. We do concede that
animal models do not always accurately reflect what will
happen in humans. Moreover, there have been notable
examples of therapeutics that appeared effective in open-
label studies until well controlled studies provided
contrary evidence [24]. Nevertheless, given the large
body of pre-clinical and open-label data in refractory
disease suggesting efficacy, we should consider whether
trial design was optimal for demonstrating benefit.
Several recent editorials have addressed the formidable
challenges of trial design in SLE [2,3,25]. No drug has
Table 1. Recent SLE randomized, controlled trials of biologics
Reference Size Study drug Endpoint Select findings
Merrill et al. [21] 257 Rituximab BILAG MCR/PCR*
at 52 weeks
No significant difference in primary and secondary endpoints; subgroup analysis
suggests benefit in black and Hispanic subjects
Merrill et al. [22] 180 Abatacept BILAG flare by
1 year
No significant difference in primary and secondary endpoints; post hoc subgroup
analysis suggests higher fraction of treated subjects on low dose prednisone without
flare during final 2 months of study
Chatham et al. [23] 449 Belimumab SELENA-SLEDAI
at 52 weeks
No significant difference in primary and secondary endpoints; post hoc subgroup
analysis suggests benefit in seropositive subjects as measured by novel SLE responder
index
*MCR = all BILAG Cs or better in every organ system at 24 weeks with maintenance of this response until week 52; PCR = all BILAG Cs or better at week
24 and maintenance for 16 weeks or at most 1 BILAG B at week 24 and maintenance until week 52. BILAG, British Isles Lupus Assessment Group; MCR,
major clinical response; PCR, partial clinical response; SELENA, Safety of Estrogen in Lupus Erythematosus National Assessment; SLE, systemic lupus
erythematosus; SLEDAI, SLE Disease Activity Index.
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do not have established methods for determining
efficacy for new drugs, especially for non-renal SLE. The
discussion that follows focuses on a number of key trial
design issues within the context of the expected
biological action of rituximab and abatacept.
Timing of endpoints
Steroids have a rapid onset of action but other agents
may take time to become effective. Indeed, the results of
the open-label extension of the belimumab trial suggest
that endpoints longer than 1 year may be necessary to
determine the full potential of biologic therapy. In
EXPLORER, greater serological improvement (anti-
dsDNA, C3, C4) was seen in patients treated with
rituximab compared to placebo by the end of the trial.
Although serological improvement was not associated
with clinical improvement, a longer trial may have found
benefit.
In the EXPLORER trial, this problem may have been
compoundedbyre-treatmentwithrituximabat6months.
One of the interesting findings from our pilot open-label
trial of rituximab in SLE was the prolonged effect on the
immune system with an expansion of transitional B-cells
at reconstitution in patients who were good long-term
responders [26]. We hypothesize that this B-cell subset
may have immunoregulatory potential. If so, re-treatment
with rituximab every 6 months would prevent the
beneficial effects of an expanded transitional cell subset.
This raises the important issue that both the timing and
choice of endpoints need to be matched to the putative
mechanism of action of the biologic agent. Even more,
one might hypothesize that the treatment should be even
more individualized, based on the degree of B-cell
depletion. We have observed various degrees of residual
memory B-cells in our rituximab-treated SLE patients,
which we believe may adversely affect outcomes [27].
Choice of endpoints
None of the primary outcome measures used in any of
the three discussed trials had been validated in clinical
trials. Although a significant improvement in SLEDAI
score of four points should provide good evidence of
efficacy of an agent, this may not be a sensitive enough
tool especially when measured against an effective
‘placebo’. We believe the BILAG-based MCRs and PCRs
defined in the EXPLORER study are also problematic. By
these indexes, response needed to be achieved within 6
months and then maintained. However, based on the
mechanism of action of rituximab in SLE, maximal
response may not be achieved by 6 months. As
previously discussed, we believe that depletion of B
cells is responsible for only a fraction of the efficacy of
B-cell depletion therapy. Other putative critical mechan-
isms include the way the immune system reconstitutes
(in which case long follow-up will be necessary beyond 1
year) and/or indirect effects of B-cell depletion on other
arms of the immune system, like T cell subsets.
Secondary endpoints in EXPLORER (largely BILAG
based), including the time to moderate or severe
BILAG flare, and exploratory endpoints, including a
decrease in global BILAG and SLEDAI score, were also
not met. However, the abatacept study seems to suggest
that outcome indicators that use BILAG flares as the
measurement tool are also problematic, especially if a
single BILAG B flare is counted. The novel SRI defined in
the belimumab study post hoc analysis may provide a
more sensitive and accurate measure of disease response.
It notably combines the SLEDAI, the BILAG, and
Physician Global Assessment, and has apparently been
accepted by the FDA as an SLE disease assessment tool.
Additional work is necessary in the lupus community,
however, to decide upon and further validate appro-
priate composite outcome measures.
Another consideration is whether quantitative measures
of disease activity in defined organ systems would
provide more objective outcomes. Of note, ongoing
trials of rituximab and abatacept in renal lupus have the
dual advantage of hard outcomes in a more homo-
geneous population of SLE. On the other hand, outcome
measures can only be part of the problem given the
recent press release from Genentech that their study of
rituximab in lupus nephritis, LUNAR, also failed to meet
primary endpoints.
Patient population
Lupus is a very heterogeneous disease and the more
targeted our therapies become, the more we will need to
recognize subsets of patients who might benefit from any
given targeted treatment. In the case of rituximab, disease
manifestations caused directly by pathogenic antibodies
produced by long-lived plasma cells are unlikely to
improve with rituximab since this therapy does not have
significant effects on long-lived plasma cells. Based on
pre-clinical data, antibody independent mechanisms are
important in renal lupus, and short-lived plasma cells
may be the predominant source of anti-dsDNA. How-
ever, an important caveat to this is the demonstration in
murine lupus that anti-dsDNA producing plasma cells
can also be selected into the long-lived compartment
[28] and may need to be eliminated for optimal efficacy.
Open-label studies of B-cell depletion also suggest
benefit in refractory disease that has been unresponsive
to conventional treatments, including high dose steroids
and cyclophosphamide. However, it will not be possible
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raise the additional question as to whether a synergistic
effect exists between biologic agents and cyclopho-
sphamide, a point further highlighted by the recently
reported failure of LUNAR, where rituximab was
combined with mycophenolate mofetil. An ongoing
trial of humanized anti-CD20 (ocrelizumab) in lupus
nephritis may address this issue given that a subset of
patients will receive B-cell depletion therapy combined
with cyclophosphamide.
Control regimen
In both the rituximab and abatacept studies, patients had
active disease requiring treatment with moderate to high
dose steroids in both the experimental and placebo arms.
This is a reasonable design if your experimental therapy
has a very strong therapeutic effect, but could miss effects
that are still important when tested against an effective
treatment. It has been suggested by others that the use of
concomitant steroids be restricted as much as possible in
future studies and a rapid taper devised [2]. In contrast,
the belimumab study did not give a course of steroids at
study entry, possibly explaining its relative success – that
is, patients were not as sick and there was no course of
steroids to obscure the effects of the experimental drug.
Conclusions
Because of these problems, we believe the door should
not be closed on additional studies of B-cell depletion or
co-stimulatory blockade in SLE. Based on our current
knowledge future studies of biologics could include the
following: first, trials with careful attention made to
immunological biomarkers of response that allow for
treatment modifications if suboptimal effects are seen. In
particular, we are concerned about the adequacy of
depletion of memory and pathogenic B-cell subsets in
SLE after rituximab. The use of biologics needs to be
refined and optimized. If B-cell depletion is inadequate
in the majority of patients, especially in tissue sites, how
can the clinical efficacy of B-cell depletion really be
addressed? Second, additional trials of organ specific
disease where there may be less heterogeneity and better
outcome measures, for example, immune-mediated
thrombocytopenia, cutaneous lupus, and central ner-
vous system manifestations of lupus. Third, trials
selecting patients based on pathophysiology that might
be more responsive to the particular biologic, for
example, rituximab treatment may be particularly
efficacious for disease manifestations predominantly
mediated by B cells and/or short-lived plasma cells (for
example, cytopenias) but not those mediated by anti-
bodies produced by long-lived plasma cells. The failure
of rituximab in both general and now renal lupus does
raise the question of whether reducing pathogenic
autoantibodies is key to maximal treatment efficacy.
Abatacept may be particularly efficacious for T-cell
driven disease manifestations. Of course, in many cases
it may be difficult to separate disease subsets cleanly on
this basis, and there is mechanistic cross-over (for
example, indirect effects of B-cell depletion on T cells).
Fourth, long-term trials designed to test whether
rituximab or abatacept can prevent flares. Fifth, early
intervention trials designed to prevent evolution of the
autoimmune response perhaps before selection of
autoreactivity into the long-lived plasma cell pool.
Lastly, combining rituximab or abatacept with other
therapies that might be synergistic, such as low dose
cyclophosphamide. Indeed, open-label data in human
SLE suggest potential synergy between cyclophospha-
mide and rituximab, while pre-clinical data in murine
lupus nephritis suggest the same for cyclophosphamide
and abatacept [20].
In conclusion, we believe that B-cell depletion and
co-stimulatory blockade remain promising approaches
to the treatment of at least a subset of SLE. Recent
randomized clinical trials provide important informa-
tion regarding optimizing study design and upon further
analysis will hopefully yield clues regarding subsets of
disease that may be responsive to distinct biologic
approaches so that future trials may yield evidence-
based proof of efficacy.
Abbreviations
BAFF, B-cell activating factor of the TNF family; BILAG,
British Isles Lupus Assessment Group; CTLA, cytoxic
T-lymphocyte antigen; dsDNA, double-stranded DNA;
EULAR, European League Against Rheumatism; FDA,
Food and Drug Administration; MCR, major clinical
response; OMERACT, Outcome Measures in Rheumatol-
ogy; PCR, partial clinical response; SELENA, Safety of
Estrogen in Lupus Erythematosus National Assessment;
SLE, systemic lupus erythematosus; SLEDAI, Systemic
Lupus Erythematosus Disease Activity Index; SRI, SLE
responder index; TNF, tumor necrosis factor.
Competing interests
JHA has received grants from Amgen Pharmaceuticals
and Genentech for mechanistic studies in the context of
lupus clinical trials, as well as grants from Proteolix and
Vaccinex for drug development in murine models of
lupus. She has served as a consultant for Genentech,
Roche, Biogen, Proteolix, and Wyeth.
Acknowledgements
We are grateful to Inaki Sanz and John Looney for
intellectual input and stimulating discussions. We thank
Page 5 of 6
(page number not for citation purposes)
F1000 Medicine Reports 2009, 1:28 http://www.F1000.com/Reports/Medicine/content/1/28Joan Merrill for reviewing the description of the clinical
trial data and providing additional detail.
References
1. Bongu A, Chang E, Ramsey-Goldman R: Can morbidity and
mortality of SLE be improved? Best Pract Res Clin Rheumatol
2002, 16:313-32.
2. Isenberg D, Gordon C, Merrill J, Urowitz M: New therapies in
systemic lupus erythematosus – trials, troubles and tribula-
tions - working towards a solution. Lupus 2008, 17:967-70.
3. Dall’Era M, Wofsy D: Clinical trial design in systemic lupus
erythematosus. Curr Opin Rheumatol 2006, 18:476-80.
4. Bertsias G, Gordon C, Boumpas DT: Clinical trials in systemic
lupus erythematosus (SLE): lessons from the past as we
proceed to the future – the EULAR recommendations for the
management of SLE and the use of end-points in clinical
trials. Lupus 2008, 17:437-42.
5. Gordon C, Bertsias GK, Ioannidis JP, Boletis J, Bombardieri S,
Cervera R, Dostál C, Font J, Gilboe IM, Houssiau F, Huizinga TW,
Isenberg D, Kallenberg CG, Khamashta MA, Piette JC, Schneider M,
Smolen JS, Sturfelt G, Tincani A, Van Vollenhoven R, Boumpas DT:
EULAR points to consider in conducting clinical trials in
systemic lupus erythematosus. Ann Rheum Dis 2009, 68:470-6.
6. Strand V, Gladman D, Isenberg D, Petri M, Smolen J, Tugwell P:
Endpoints: consensus recommendations from OMERACT IV.
Outcome measures in rheumatology. Lupus 2000, 9:322-7.
7. US Department of Health and Human Services, Food and Drug
Administration, Center for Drug Evaluation and Research (CDER):
Guidance for Industry: Systemic Lupus Erythematosus –
Developing Drugs for Treatment. March 2005. [www.fda.gov/
cder/guidance/6496dft.pdf].
8. Chan OT, Madaio MP, Shlomchik MJ: The central and multiple
roles of B cells in lupus pathogenesis. Immunol Rev 1999,
169:107-21.
9. Shlomchik MJ, Madaio MP, Ni D, Trounstein M, Huszar D: The role
of B cells in lpr/lpr-induced autoimmunity. J Exp Med 1994,
180:1295-306.
10. Looney RJ, Anolik JH, Campbell D, Felgar RE, Young F, Arend LJ,
Sloand JA, Rosenblatt J, Sanz I: B cell depletion as a novel
treatment for systemic lupus erythematosus: A phase I/II
dose-escalation trial of rituximab. Arthritis Rheum 2004,
50:2580-9.
11. Isenberg DA: Treating patients with lupus with B-cell deple-
tion. Lupus 2008, 17:400-4.
12. Lindholm C, Borjesson-Asp K, Zendjanchi K, Sundqvist AC,
Tarkowski A, Bokarewa M: Longterm clinical and immunologi-
cal effects of anti-CD20 treatment in patients with refractory
systemic lupus erythematosus. J Rheumatol 2008, 35:826-33.
13. Tokunaga M, Saito K, Kawabata D, Imura Y, Fujii T, Nakayamada S,
Tsujimura S, Nawata M, Iwata S, Azuma T, Mimori T, Tanaka Y:
Efficacy of rituximab (anti-CD20) for refractory systemic
lupus erythematosus involving the central nervous system.
Ann Rheum Dis 2007, 66:470-5.
F1000 Factor 3.0 Recommended
Evaluated by Gyorgy Nagy 31 May 2007
14. Podolskaya A, Stadermann M, Pilkington C, Marks SD, Tullus K: B cell
depletion therapy for 19 patients with refractory systemic
lupus erythematosus. Arch Dis Child 2008, 93:401-6.
15. Jónsdóttir T, Gunnarsson I, Risselada A, Henriksson EW, Klareskog L,
van Vollenhoven RF: Treatment of refractory SLE with
rituximab plus cyclophosphamide: clinical effects, serological
changes, and predictors of response. Ann Rheum Dis 2007,
67:330-4.
16. Amoura Z, Mazodier K, Michel M, Viallard J-F, Huong D,
Chalumeau N, Cacoub P, Harle JR, Pellegrin JL, Kaplanski G,
Godeau B, Piette JC: Efficacy of rituximab in systemic lupus
erythematosus: a series of 22 cases. Arthritis Rheum 2007, 56:
S458.
17. Mackay F, Woodcock SA, Lawton P, Ambrose C, Baetscher M,
Schneider P, Tschopp J, Browning JL: Mice transgenic for BAFF
develop lymphocytic disorders along with autoimmune
manifestations. J Exp Med 1999, 190:1697-710.
18. Gross J, Johnston J, Mudri S, Enselman R, Dillon SR, Madden K, Xu W,
Parrish-Novak J, Foster D, Lofton-Day C, Moore M, Littau A,
Grossman A, Haugen H, Foley K, Blumberg H, Harrison K,
Kindsvogel W, Clegg CH: TACI and BCMA are receptors for a
TNF homologue implicated in B-cell autoimmune disease.
Nature 2000, 404:995-9.
19. Kremer JM, Westhovens R, Leon M, Di Giorgio E, Alten R, Steinfeld S,
Russell A, Dougados M, Emery P, Nuamah IF, Williams GR, Becker JC,
Hagerty DT, Moreland LW: Treatment of rheumatoid arthritis
by selective inhibition of T-cell activation with fusion protein
CTLA4Ig. New Engl J Med 2003, 349:1907-15.
20. Daikh DI, Wofsy D: Cutting edge: reversal of murine lupus
nephritis with CTLA4Ig and cyclophosphamide. J Immunol
2001, 166:2913-6.
21. Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM,
Oates JC, Utset TO, Gordon C, Isenberg DA, Hsieh HJ, Zhang D,
Brunetta PG: Efficacy and safety of rituximab in patients with
moderately to severely active systemic lupus erythematosus:
results from the randomized, double-blind phase II/III study
EXPLORER. Presented at 72nd Annual Scientific Meeting of the
American College of Rheumatology; October 24–29, 2008; San
Francisco, CA. Abstract L12.
22. Merrill JT, Burgos-Vargas R, Westhovens R, Chalmers A, D’Cruz D,
Wallace D, Bae SC, Sigal L, Becker JC, Kelly S, Raghupathi K, Peng Y,
Kinaszczuk M, Nash P: The efficacy and safety of abatacept in
SLE: results of a 12-month exploratory study. Presented at
72nd Annual Scientific Meeting of the American College of
Rheumatology; October 24–29, 2008; San Francisco, CA. Abstract
L15.
23. Chatham W, Furie R, Petri M, Ginzler EM, Wallace DJ, Stohl W,
Strand V, Weinstein A, Zhong J, Hough D, Freimuth W: Belimumab
(fully human monoclonal antibody to BLyS) improved or
stabilized systemic lupus erythematosus (SLE) disease activ-
ity over 3 years of therapy. Arthritis Rheum 2008, 58:S1088.
24. Wegener’s Granulomatosis Etanercept Trial (WGET) Research
Group: Etanercept plus standard therapy for Wegener’s
granulomatosis. N Engl J Med 2005, 352:351-61.
25. Yuen SY, Pope JE: Learning from past mistakes: assessing trial
quality, power and eligibility in non-renal systemic lupus
erythematosus randomized controlled trials. Rheumatology
2008, 47:1367-72.
26. Anolik JH, Barnard J, Owen T, Zheng B, Kemshetti S, Looney RJ,
Sanz I: Delayed memory B cell recovery in peripheral blood
and lymphoid tissue in systemic lupus erythematosus after B
cell depletion therapy. Arthritis Rheum 2007, 56:3044-56.
27. Anolik JH, Barnard J, Cappione A, Pugh-Bernard AE, Felgar RE,
Looney RJ, Sanz I: Rituximab improves peripheral B cell
abnormalities in human systemic lupus erythematosus.
Arthritis Rheum 2004, 50:3580-90.
28. Hoyer BF, Moser K, Hauser AE, Peddinghaus A, Voigt C, Eilat D,
Radbruch A, Hiepe F, Manz RA: Short-lived plasmablasts and
long-lived plasma cells contribute to chronic humoral
autoimmunity in NZB/W mice. J Exp Med 2004, 199:1577-84.
F1000 Factor 3.0 Recommended
Evaluated by Ken Smith 17 Jun 2004
Page 6 of 6
(page number not for citation purposes)
F1000 Medicine Reports 2009, 1:28 http://www.F1000.com/Reports/Medicine/content/1/28